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Summary
Background  and  purpose:  Recently,  serum  deoxyribonuclease  I  (DNase  I)  activity  has  been  high-
lighted as  a  potential  diagnostic  marker  for  transient  myocardial  ischemia.  To  evaluate  whether
serum DNase  I  activity  can  be  a  useful  biomarker  for  diagnosing  unstable  angina  pectoris  (UAP)
or non—ST-segment  elevation  myocardial  infarction  (NSTEMI),  we  investigated  serial  changes  in
DNase I  levels  after  chest  pain  in  UAP  and  NSTEMI  (UAP/NSTEMI)  patients.
Methods  and  results:  Thirty-three  and  ten  patients  classiﬁed  into  the  UAP/NSTEMI  and  the
chest pain  syndrome  (CPS)  group,  respectively,  were  enrolled.  The  serum  DNase  I  activity  levels
within 3  h  after  chest  pain  and  the  absolute  median  value  of  percentage  differences  in  serum
DNase I  activity  levels  from  admission  to  3  h  after  hospitalization  in  the  UAP/NSTEMI  patients
was signiﬁcantly  higher  than  those  in  the  CPS  patients.  We  evaluated  the  patients  to  show
positive  results  for  DNase  I activity  if  the  serum  levels  or  percentage  differences  exceeded  the
corresponding  cut-off  values.  The  sensitivity  and  speciﬁcity  of  DNase  I within  6  h  after  chest
pain in  the  UAP/NSTEMI  patients  without  elevated  levels  of  cardiac  troponin  T  and  the  MB
isoenzyme  of  creatine  kinase  were  89%  and  88%,  respectively.
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Conclusions:  Serum  DNase  I  activity  can  be  a  useful  marker  for  the  early  diagnosis  of  UAP/NSTEMI
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to  3  h after  admission.  The  upper  limit  of  the  normal  range
of  intra-individual  percentage  difference  was  estimated  to
be  a  tentative  cut-off  value  of  12.4%  [7].  If  the  absoluteafter the  onset  of  chest  pain
© 2012  Japanese  College  of  C
Introduction
Because  unstable  angina  pectoris  (UAP)  and  non—ST-
segment  elevation  myocardial  infarction  (NSTEMI)  are
associated  with  an  increased  risk  of  acute  myocardial  infarc-
tion  (AMI)  and  subsequent  cardiac  death,  it  is  important
to  perform  prompt  evaluation  for  managing  patients  with
these  conditions.  Chest  symptoms,  cardiac  biomarkers,  and
electrocardiograms  (ECGs)  are  the  main  factors  that  aid
early  diagnosis  of  UAP  and  NSTEMI  (UAP/NSTEMI).  However,
some  UAP/NSTEMI  patients  do  not  present  with  chest  symp-
toms,  elevated  levels  of  cardiac  biomarkers,  and  abnormal
ECGs  ﬁndings  on  admission.  These  patients  are  categorized
as  patients  with  short-term  low  risk  of  death  or  nonfatal
MI  and  recommended  to  undergo  short-term  observation
at  the  emergency  department  [1—4]. However,  for  further
improvement  in  initial  diagnosis  and  risk  stratiﬁcation,  we
require  useful  biomarkers  that  can  preclude  a  non-cardiac
cause  and  conﬁrm  the  diagnosis  of  UAP/NSTEMI.
In  our  previous  study,  abrupt  elevation  of  serum  deoxyri-
bonuclease  I [5]  (DNase  I,  EC  3.1.21.1)  activity  levels
occurred  within  approximately  3  h  after  chest  pain  onset
in  AMI  patients.  Thereafter  serum  DNase  I  activity  levels
showed  a  time-dependent  decline  within  12  h  and  returned
to  the  basal  level  within  24  h  [6].  Furthermore,  the  serum
DNase  I activity  levels  increased  signiﬁcantly  from  the  basal
level  within  3  h  after  percutaneous  coronary  intervention
(PCI)  and  vasospastic  angina  pectoris  (VSAP)  provocation
test,  irrespective  of  any  alterations  in  creatine  kinase
(CK)-MB  and  cardiac  troponin  T  (c-TnT)  levels  [7,8]. We
consider  serum  DNase  I  as  a  biomarker  for  transient  myocar-
dial  ischemia  rather  than  for  myocardial  necrosis.  Until
recently,  biomarkers  capable  of  detecting  transient  myocar-
dial  ischemia,  especially  in  UAP/NSTEMI  patients  without
chest  pain,  elevated  levels  of  cardiac  biomarkers,  and
abnormal  ECGs  ﬁndings  had  not  been  reported.  Thus,  on  the
basis  of  the  results  of  our  previous  studies  [6—9], we  consid-
ered  DNase  I  as  a  biomarker  for  the  diagnosis  of  UAP/NSTEMI
and  investigated  serial  changes  in  serum  DNase  I  activity
levels  in  UAP/NSTEMI  patients.
Materials and methods
Subjects
Between  March  2007  and  April  2009,  166  consecutive
Japanese  patients  suspected  of  having  acute  coronary  syn-
drome  were  admitted  to  our  hospitals.  Among  them,  52
patients  with  chest  pain  within  24  h  before  admission  and
suspected  to  have  UAP/NSTEMI  were  enrolled.  All  patients
with  suspected  UAP/NSTEMI  experienced  rest  angina,  new-
onset  severe  angina,  or  increased  angina.  The  diagnosis
of  UAP/NSTEMI  was  based  on  the  presence  of  electro-
cardiographic  ST-segment  depression  or  prominent  T-wave
inversion  and/or  positive  biomarkers  of  necrosis  in  the
absence  of  ST-segment  elevation  [4].  Emergency  coronary
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ngiography  (CAG)  was  performed  to  conﬁrm  the  pres-
nce  of  organic  coronary  stenosis.  Nine  patients  without  ST
levation  on  ECG  but  with  total  occlusion  of  the  left  cir-
umﬂex  coronary  artery  on  CAG  were  excluded.  Twelve  of
he  remaining  43  patients  were  found  to  have  no  signiﬁ-
ant  organic  stenosis  (≤50%)  on  CAG  and  were  subjected
o  the  acetylcholine  (Ach)  provocation  test,  because  coro-
ary  vasospasm  can  be  an  important  cause  of  UAP/NSTEMI
10].  Two  patients  were  diagnosed  with  VSAP  because  they
howed  a  transient,  total  or  near-total  occlusion  of  the
rovoked  coronary  artery.  The  remaining  10  patients  were
lassiﬁed  into  the  chest  pain  syndrome  (CPS)  group  (con-
rol).  Thirty-three  patients  [31  patients  with  signiﬁcant
oronary  stenosis  (>50%)  and  2  patients  with  VSAP]  were
lassiﬁed  into  the  UAP/NSTEMI  group.
Based  on  the  time-dependent  alterations  in  serum  DNase
 activity  levels  after  the  onset  of  myocardium  ischemia
6—9], we  further  divided  the  UAP/NSTEMI  and  CPS  patients
nto  3  groups  and  compared  the  serum  DNase  I  activity
evels.  Group  1  comprised  patients  who  were  hospitalized
ithin  3  h  after  the  onset  of  chest  pain,  group  2  comprised
atients  who  were  hospitalized  3—6  h  after  the  onset  of
hest  pain,  and  group  3  comprised  patients  who  were  hospi-
alized  more  than  6  h  after  on  the  onset  of  chest  pain.  Group
 comprised  15  UAP/NSTEMI  patients  and  5  CPS  patients,
roup  2,  10  UAP/NSTEMI  patients  and  3  CPS  patients,  and
roup  3,  8  UAP/NSTEMI  patients  and  2  CPS  patients.
The  study  protocol  conformed  to  the  Declaration  of
elsinki  and  was  approved  by  the  Human  Ethics  Committee
f  the  institutes  and  all  the  patients  gave  written  informed
onsent.
ollection  of  blood  samples  and  measurement  of
he levels  of  serum  DNase  I  activity  and  other
ardiac biomarkers
lood  samples  were  collected  from  the  patients  soon  after
dmission  and  after  3,  6,  12,  and  24  h.  Serum  samples  were
repared  from  each  blood  sample  by  using  centrifugation
nd  were  stored  at  −80 ◦C  until  assay.
DNase  I  activity  levels  in  the  serum  samples  were
easured  using  the  single  radial  enzyme  diffusion  (SRED)
ethod,  as  described  previously  [11]. We  previously  deter-
ined  the  upper  limit  of  the  normal  range  of  serum  DNase  I
ctivity  to  be  17.9  U/L  [6].  On  admission,  if  a  patient’s  DNase
 activity  level  exceeded  the  cut-off  level,  then  the  patient
as  considered  positive  for  elevation  in  the  DNase  I  activity
evel.  In  addition,  we  evaluated  percentage  differences  in
he  serum  DNase  I  activity  levels  from  the  time  of  admissionalue  of  percentage  differences  in  serum  DNase  I  activity
evels  exceeded  the  cut-off  level,  then  the  patient  was  con-
idered  positive  for  alteration  in  DNase  I activity  levels.
erum  concentration  of  CK-MB  and  c-TnT  were  determined,
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Table  1  Clinical  characteristics  of  the  study  patients.
UAP/NSTEMI  CPS  p
Total  population  (n)  33  10
Age (years,  mean  ±  SD)  62.9  ±  11.5  61.3  ±  20.4  0.75
Men (n,  %)  27  (82)  8  (80)  0.89
Coronary risk  factors  (n,  %)
Cigarette  smoking  16  (48)  3  (30)  0.30
Diabetes mellitus 19  (58)  1  (10)  0.0075
Hypertension 29 (88)  3  (30)  0.0002
Hypercholesterolemia 19 (58)  3 (30)  0.126
Obesity 13 (39)  4 (40)  0.97
Interval between  the  onset  of  the  last  chest  pain
episode  and  admission  (h,  mean  ±  SD)
6.2  ±  5.9  4.1  ±  6.6  0.34
Chest pain  on  admission  (n,  %)  16  (48)  8  (80)  0.08
Abnormal ECG  ﬁndings  (n,  %)
ST depression  17  (52)  1  (10)  0.019
ST elevation  0  (0)  3  (30)  0.001
T-wave inversion  9  (27)  1  (10)  0.20
RBBB 2  (6)  1  (10)  0.67
cTnT >  0.1  ng/mL  on  admission  (n,  %)  17  (52)  0  (0)  0.003
CK-MB >  25  U/L  on  admission  (n,  %)  7  (21)  1  (10)  0.42
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iUAP/NSTEMI, unstable angina pectoris and non—ST-segment elev
cardiogram; RBBB, right bundle branch block; c-TnT, cardiac trop
s  described  previously  [6].  Cut-off  levels  of  CK-MB  and  c-
nT  that  were  indicative  of  positive  activity  were  25  U/L  and
.01  g/L,  respectively  [12,13].
tatistical  analyses
he  data  are  expressed  as  mean  ±  SD  values.  The  Student’s
-test  was  used  to  compare  the  values  of  the  2 groups.  Per-
entage  differences  in  serum  DNase  I  activity  levels  from  the
aseline  to  3  h  after  admission  were  used  to  clearly  reﬂect
he  variability  in  the  levels  in  a  patient,  and  were  expressed
s  the  absolute  value  of  median  and  25th  and  75th  percentile
ange.  The  value  was  calculated  as  follows:  (assay  level  at
 h  after  admission  −  assay  level  on  admission)  ×  100/assay
evel  on  admission.
The  Tukey—Kramer  multiple  comparison  test  was  used
o  assess  the  differences  in  the  values  measured  on  admis-
ion  and  at  3  h  after  admission.  Categorical  variables  of  the
atient’s  clinical  background  were  compared  using  the  2
est  or  a  nonparametric  test.  Data  analysis  was  performed
sing  the  StatView  software,  version  5.0  and  R  software,
ersion  2.5.1  (http://www.r-project.org/). The  differences
ere  examined  using  a  two-sided  test  at  a  signiﬁcance  level
f  0.05.
esults
linical  characteristics  of  the  study  group
he  clinical  characteristics  of  the  UAP/NSTEMI  and  CPS
atients  are  listed  in  Table  1.  Intergroup  differences  in  mean
ge,  sex,  and  interval  between  the  onset  of  the  last  chest
ain  episode  and  admission  were  not  signiﬁcant.  On  admis-
ion,  48%  of  the  UAP/NSTEMI  group  and  80%  of  the  CPS  group
t
r
n
l myocardial infarction; CPS, chest pain syndrome; ECG, electro-
T; CK-MB, MB isoenzyme of creatine kinase.
xperienced  chest  pain.  However,  intergroup  differences  in
hest  pain  on  admission  were  not  signiﬁcant.  The  number  of
atients  showing  ST  depression  on  the  ECGs  was  signiﬁcantly
reater  in  the  UAP/NSTEMI  group  than  in  the  CPS  group.
nterestingly,  3  patients  of  the  CPS  group  showed  ST  eleva-
ion,  which  was  later  considered  as  early  depolarization,  in
he  ECG.
lterations  in  serum  DNase  I activity  levels  during
he clinical  course
hanges  in  the  serum  DNase  I  activity  levels  after  the  last
hest  pain  episode  in  UAP/NSTEMI  and  CPS  patients  are
hown  in  Fig.  1A  and  B,  respectively.  The  serum  DNase
 activity  levels  peaked  within  6  h  after  the  last  onset
f  chest  pain  in  most  UAP/NSTEMI  patients,  thereafter
howing  a  time  dependent  decline,  and  a  return  to  the
asal  level  within  24  h.  These  ﬁndings  were  similar  to
hose  of  alteration  of  serum  DNase  I  activity  levels  in  pre-
iously  studied  AMI  patients  [6,9]. However,  there  were
o  signiﬁcant  changes  in  the  serum  DNase  I  activity  lev-
ls  of  the  CPS  patients  during  their  clinical  courses.  On
dmission,  the  mean  serum  DNase  I  activity  levels  were  sig-
iﬁcantly  higher  in  the  UAP/NSTEMI  patients  than  in  the
PS  patients  (16.0  ±  9.5  U/L  vs.  9.5  ±  2.5  U/L,  respectively,
 =  0.04)  (Fig.  2).  Furthermore,  we  performed  a  detailed
valuation  of  the  serum  DNase  I  levels  in  3  time  windows
fter  the  last  chest  pain  episode.  In  group  1  hospitalized
ithin  3  h  after  the  episode,  the  serum  DNase  I  activity  levels
n  the  UAP/NSTEMI  patients  were  signiﬁcantly  higher  than
hose  in  the  CPS  patients  (19.3  ±  11.2  U/L  vs.  8.4  ±  1.5  U/L,
espectively,  p  =  0.047).  However,  in  groups  2  and  3,  no  sig-
iﬁcant  differences  were  found  between  the  serum  DNase  I
evels  of  the  UAP/NSTEMI  and  CPS  patients  (Fig.  3A—C).
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Figure  1  Serial  changes  in  the  serum  DNase  I  activity  level
as a  function  of  time  from  the  onset  of  chest  pain  in  33  unsta-
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Figure  2  Scatter-diagram  of  serum  DNase  I  activity  levels
detected  on  admission  in  the  unstable  angina  pectoris  and
non—ST-segment  elevation  myocardial  infarction  and  chest  pain
syndrome  patients.  Bar  and  broken  line  represent  mean  ±  SD
values and  the  upper  limit  of  the  normal  range,  respectively.
d
v
i
(
s
g
(
i
p
(
a
w
f
f
t
(
r
m
(ble angina  pectoris  and  non—ST-segment  elevation  myocardial
infarction  patients  (A)  and  10  chest  pain  patients  (B).
The  use  of  serum  DNase  I  in  the  diagnosis  of
UAP/NSTEMI
Among  the  UAP/NSTEMI  patients,  7  (47%)  patients  in  group
1,  3  (30%)  in  group  2,  and  2  (25%)  in  group  3  were  posi-
tive  for  elevated  serum  DNase  I  activity  levels  (Table  2).  We
had  previously  shown  that  percentage  differences  in  serum
DNase  I  activity  levels  were  more  effective  than  elevated
serum  DNase  I  activity  levels  for  detecting  transient  myocar-
dial  ischaemia  [7,8]. Therefore,  in  this  study,  we  evaluated
the  percentage  differences  in  serum  DNase  I  activity  lev-
els  from  the  time  of  admission  to  3  h  after  admission  in
both  UAP/NSTEMI  and  CPS  groups  to  increase  the  efﬁcacy  of
d
8
5
riagnosis.  In  the  UAP/NSTEMI  group,  the  absolute  median
alue  of  the  percentage  differences  in  serum  DNase  I  activ-
ty  level  from  the  baseline  to  3  h  after  admission  was  18.1%
25th  percentile:  9.7%;  75th  percentile:  36%),  showing  a
igniﬁcant  change  (p  =  0.02)  (Fig.  4A).  However,  the  CPS
roup  showed  no  signiﬁcant  change  in  DNase  I activity  levels
Fig.  4B).  Among  the  UAP/NSTEMI  patients,  10  (67%)  patients
n  group  1,  6  (60%)  in  group  2,  and  4  (50%)  in  group  3  showed
ositive  results  for  alteration  in  serum  DNase  I activity  levels
Table  2).
To  evaluate  the  diagnostic  efﬁcacy  of  serum  DNase  I
ctivity  levels  in  the  UAP/NSTEMI  and  CPS  groups  in  3  time
indows,  we  considered  the  patients  to  show  positive  results
or  DNase  I  activity  if  the  serum  levels  or  percentage  dif-
erences  exceeded  the  corresponding  cut-off  values.  Among
he  UAP/NSTEMI  patients,  12  (80%)  patients  in  group  1,  7
70%)  in  group  2,  and  4  (50%)  in  group  3  showed  positive
esults  for  DNase  I.  On  the  basis  of  these  results,  we  esti-
ated  the  sensitivity,  speciﬁcity,  positive  predictive  value
PPV),  and  negative  predictive  value  (NPV)  of  DNase  I for  the
iagnosis  of  UAP/NSTEMI  in  the  3  time  windows  (Table  3)  as
0%,  80%,  92%,  and  67%  in  group  1,  70%,  100%,  100%,  and
0%,  in  group  2,  and  50%,  100%,  100%,  and  33%  in  group  3,
espectively.
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Table  2  Number  of  UAP/NSTEMI  patients  with  serum  DNase  I  activity  levels  above  the  cut-off  levels  in  the  3  time  windows.
UAP/NSTEMI CPS
Group  1  Group  2  Group  3  Group  1  Group  2  Group  3
(n =  15) (n  =  10) (n  =  8) (n  =  5)  (n  =  3)  (n  =  2)
Positive  result  for  elevation  in  DNase  I  activity
levels  (n,  %)
7  (47) 3 (30)  2 (25)  0  0  0
Positive result  for  alteration  in  DNase  I  activity
levels  (n,  %)
10  (67)  6  (60)  4  (50)  1  (20)  0  0
Positive result  for  DNase  I  (n,  %)  12  (80)  7  (70)  4  (50)  1  (20)  0  0
UAP/NSTEMI, unstable angina pectoris and non—ST-segment elevation myocardial infarction; CPS, chest pain syndrome.
Positive result for elevation in DNase I activity levels: serum DNase I activity levels on admission, >17.9 U/L. Positive result for alteration
in DNase I activity levels: absolute value of percentage differences from baseline to 3 h after admission, >12.4%. Positive result for DNase
I: positive result for elevation or alteration in DNase I activity levels.
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Figure  3  Scatter-diagram  of  the  DNase  I  acitivity  levels  detected  in  3  time  windows  (A—C)  in  the  unstable  angina  pectoris  and
non—ST-segment  elevation  myocardial  infarction  and  chest  pain  syndrome  patients.  Bar  and  broken  line  represent  mean  ±  SD  values
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omparison  with  other  cardiac  biomarkers
e  compared  the  sensitivity,  speciﬁcity,  PPV,  and  NPV  val-
es  of  c-TnT  and  CK-MB  for  the  diagnosis  of  UAP/NSTEMI  in
he  3  time  windows  with  those  of  serum  DNase  I (Table  3).  In
roup  1  and  group  2,  DNase  I  had  higher  diagnostic  efﬁcacy,
specially  with  regard  to  sensitivity,  than  c-TnT  and  CK-MB.
herefore,  we  evaluated  the  diagnostic  efﬁcacy  of  DNase  I
r
o
t
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Table  3  Diagnostic  efﬁcacy  of  serum  DNase  I  activity,  c-TnT  and  
Group  1  Group  2  
DNase  I  c-TnT  CK-MB  DNase  I  
Sensitivity  (%)  80  45  20  70  
Speciﬁcity (%)  80  100  100  100  
PPV (%)  92  100  100  100  
NPV (%)  67  38  29  50  
c-TnT, cardiac troponin T; CK-MB, MB isoenzyme of creatine kinase; PP
The diagnostic efﬁcacy in each group was calculated on the basis of pon group  1  and  2  patients  who  did  not  show  elevated  levels
f  c-TnT  or  CK-MB  on  admission.  Nine  of  25  patients  (36%)  in
roups  1  and  2  did  not  show  elevated  c-TnT  or  CK-MB  levels
n  admission  and  8  of  the  9  patients  (89%)  showed  positive
esults  for  DNase  I.  The  criteria  for  diagnosing  UAP/NSTEMI
n  the  basis  of  DNase  I  activity  levels  were  as  follows:  sensi-
ivity,  89%;  speciﬁcity,  88%;  PPV  value,  89%;  and  NPV  value,
8%.
CK-MB  levels  in  the  3  time  windows.
Group  3
c-TnT  CK-MB  DNase  I  c-TnT  CK-MB
60  20  50  50  25
100  100  100  100  100
100  100  100  100  100
43  27  33  33  25
V, positive predictive value; NPV, negative predictive value.
sitive and negative results for DNase I.
DNase  I  as  a  diagnostic  marker  for  UAP/NSTEMI  
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Figure  4  Absolute  values  of  percentage  differences  in  serum
DNase  I  activity  level  from  the  baseline  to  3  h  after  admis-
sion.  Broken  line  represents  the  upper  limit  of  the  normal
range  of  intra-individual  variation  in  serum  DNase  I  activity.
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tered  nitroglycerin  (NTG)  immediately  after  admission.  TheUAP/NSTEMI,  unstable  angina  pectoris  and  non—ST-segment
elevation  myocardial  infarction;  CPS,  chest  pain  syndrome.
Discussion
Major  ﬁndings
Among  the  patients  who  were  hospitalized  within  3  h  of  the
last  chest  pain  episode,  the  mean  serum  DNase  I  activity
levels  and  the  percentage  differences  in  DNase  I  levels  from
the  baseline  to  3  h  after  admission  were  signiﬁcantly  higher
p
i
t263
n the  UAP/NSTEMI  group  than  in  the  CPS  group.  We  com-
ined  2  criteria,  elevation  in  the  DNase  I  activity  levels  and
igniﬁcant  percentage  differences  in  DNase  I  levels  from  the
aseline  to  3  h  after  admission  to  improve  the  diagnostic
fﬁcacy  of  serum  DNase  I in  the  UAP/NSTEMI  group;  among
he  UAP/NSTEMI  patients  hospitalized  within  3  h  after  the
ast  chest  pain  episode,  80%  of  the  patients  showed  positive
esults  for  DNase  I.  Furthermore,  a  relative  high  diagnos-
ic  efﬁcacy  of  DNase  I  was  observed  in  the  early  phase,
ven  in  UAP/NSTEMI  patients  who  did  not  show  elevated
evels  of  conventional  cardiac  biomarkers.  These  ﬁndings
ndicated  that  serum  DNase  I  level  is  an  excellent  biomarker
or  detecting  myocardial  ischemia  in  UAP/NSTEMI  patients
specially  in  the  early  phase  after  the  onset  of  chest  pain,
rrespective  of  the  evidence  of  myocardial  injury.
valuation  of  serum  DNase  I  activity  level  as  a
iomarker for  UAP/NSTEMI  diagnosis
AP/NSTEMI  is  a  well-known  life-threatening  disorder;  how-
ver,  absence  of  typical  chest  pain,  ST-segment  shift,
egional  wall-motion  abnormalities,  and  elevated  cardiac
arker  levels  frequently  makes  the  deﬁnitive  diagnosis  of
AP/NSTEMI  difﬁcult  [4].  An  ideal  biomarker  for  myocar-
ial  ischemia  is  one  that  aids  early  detection  of  ischemia
fter  the  onset  of  chest  pain.  Furthermore,  the  level  of
he  biomarker  should  decrease  within  approximately  24  h  so
hat  recurrent  ischemia  can  be  detected  and  exacerbation
f  stable  coronary  disease  due  to  exertional  ischemia  can  be
inimized  [14]. Serum  DNase  I  could  be  a  useful  diagnostic
arker  for  UAP/NSTEMI  that  causes  myocardial  ischemia  in
he  early  phase  after  the  onset  of  chest  pain.  The  diagnosis
f  UAP/NSTEMI  in  the  other  time  windows  (3—24  h  after  the
nset  of  chest  pain)  could  be  supplemented  by  changes  in
-TnT  or  CK-MB  level  or  abnormal  ECG  ﬁndings.  Myoglobin,
 low-molecular-weight  haem  protein  found  in  both  cardiac
nd  skeletal  muscles,  is  a  well-known  cardiac  marker  that
an  be  detected  as  early  as  2 h  after  the  onset  of  myocardial
ecrosis;  however,  myoglobin  is  not  cardiac-speciﬁc  [15,16].
n  the  other  hand,  our  previous  studies  indicate  that  serum
Nase  I  activity  is  more  sensitive  and  speciﬁc  for  myocardial
schemia;  signiﬁcant  alterations  in  serum  DNase  I activity
ould  be  induced  by  occurrence  of  myocardial  ischemia,
rrespective  of  the  evidence  of  myocardial  injury.
DNase  I  is  stored  in  the  secretory  granules  of  the  cells
nd  is  secreted  into  the  lumen  [17,18]. It  is  plausible  to
uggest  that  DNase  I  may  be  secreted  from  granules  in  the
yocardium  as  well  as  brain  natriuretic  peptide,  when  trig-
ered  by  myocardial  ischemia,  and  may  take  time  until
t  can  be  stored  in  the  granules  after  its  secretion.  Two
AP/NSTEMI  patients  in  this  study  might  exhibit  no  elevation
f  serum  DNase  I  activity  levels  in  the  early  phase  after  chest
ain,  maybe  due  to  DNase  I  secretion  induced  by  prodromal
ngina  before  the  last  chest  pain  episode.
Furthermore,  only  1  CPS  patient  showed  signiﬁcant  ele-
ation  in  serum  DNase  I  activity  level  (Table  2).  The  patient
as  hospitalized  with  prolonged  chest  pain  and  was  adminis-atient’s  Ach  provocation  showed  negative  results;  however
t  is  possible  that  VSAP  could  not  be  diagnosed  because  of
he  effect  of  NTG.
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[64  
According  to  the  Thrombolysis  in  Myocardial  Infarction
isk  score  for  UAP/NSTEMI  patients  who  did  not  show  ST-
egment  deviation  on  ECG  and  elevated  levels  of  serum
ardiac  biomarkers  on  admission,  they  belonged  to  the  low-
isk  groups  [3].  However,  because  of  the  relatively  high
iagnostic  efﬁcacy  of  DNase  I  in  such  patients,  serum  DNase
 activity  may  prove  to  be  a  tool  for  risk  stratiﬁcation  and
ay  improve  the  prognosis  of  UAP/NSTEMI  patients  by  aiding
arly  diagnosis.
tudy  limitations
ne  of  the  features  that  favor  the  diagnostic  performance
f  cardiac  biomarkers  in  UAP/NSTEMI  patients  is  a  rapid
nd  easy  assay  [19]. In  this  study,  approximately  20  h  are
equired  to  obtain  the  results  by  using  the  SRED  method.
herefore,  more  rapid  DNase  I  detection  kits  need  to  be
eveloped  for  clinical  application.
The  study  sample  size  used  in  our  study  was  small.  Fur-
her  studies  with  large  samples  are  required  to  evaluate
hether  serum  DNase  I  level  is  a  clinically  useful  diagnos-
ic  marker  for  UAP/NSTEMI  including  comparison  with  other
ecent  cardiac  markers  [20,21].
onclusions
 high  diagnostic  efﬁcacy  of  serum  DNase  I  activity  levels
ould  be  observed  in  the  early  phase,  even  in  UAP/NSTEMI
atients  who  did  not  show  elevated  levels  of  conventional
ardiac  biomarkers.  Thus,  serum  DNase  I  activity  level  can
e  a  useful  marker  for  the  early  diagnosis  of  UAP/NSTEMI
fter  the  onset  of  chest  pain,  irrespective  of  the  evidence
f  myocardial  injury.
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